Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5601453 | 0.96 | — | — | |
| SCHEMBL5602106 | 0.87 | — | — | |
| SCHEMBL7232312 | 0.78 | MAPK1 (0.56) | MAPK1ALDH1A1HSD17B10CES2CES1 | |
| SCHEMBL18643579 | 0.78 | — | — | |
| SCHEMBL3075445 | 0.78 | — | — | |
| SCHEMBL15907943 | 0.78 | MAPK1 (0.56) | MAPK1ALDH1A1HSD17B10CES2CES1 | |
| SCHEMBL7224887 | 0.78 | — | — | |
| SCHEMBL862038 | 0.78 | — | — | |
| SCHEMBL10635076 | 0.77 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL22766217 | 0.73 | MAPK1 (0.33) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191846-B2 | Methods of treatment utilizing biocompatible nanoparticles and therapeutic agents | CURADIGM SAS (FR) | 2021-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191846-B2 | Methods of treatment utilizing biocompatible nanoparticles and therapeutic agents | ALB, CD47, CD63 | MAPK1 2335/4885ALDH1A1 462/4885HSD17B10 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.